Evidence map›Paper›PMID 32883593›Full record

Trial reportTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2020

SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma.

Latha Dulipsingh, Danyal Ibrahim, Ernst J Schaefer, Rebecca Crowell, Margaret R Diffenderfer, Kendra Williams, Colleen Lima, Jessica McKenzie, Lisa Cook, Jennifer Puff and 6 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04343261 (Convalescent Plasma in the Treatment of COVID 19), which is not on this map. Cited by 20 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 6 pooled it
0.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04343261 phase2completednot on this map

Convalescent Plasma in the Treatment of COVID 19

TypeinterventionalSponsorTrinity Health Of New EnglandRan2020 to 2020Enrolled48ConditionsSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID, CoronavirusArmsConvalescent Plasma
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 6 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Time-dependent decay of detectable antibodies against SARS-CoV-2: A comparison of ELISA with two batches of a lateral-flow test.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Latha DulipsinghDiabetes and Endocrinology Center, Saint Francis Hospital and Medical Center, Hartford, CT, United States. Electronic address: Latha.Dulipsingh@trinityhealthofne.org.
Danyal IbrahimTrinity Health Of New England, Hartford, CT, United States.
Ernst J SchaeferBoston Heart Diagnostics, Framingham, MA, United States.
Rebecca CrowellResearch Department, Saint Francis Hospital and Medical Center, Hartford CT, United States.
Margaret R DiffenderferBoston Heart Diagnostics, Framingham, MA, United States.
Kendra WilliamsResearch Department, Saint Francis Hospital and Medical Center, Hartford CT, United States.
Colleen LimaTrinity Health Of New England, Hartford, CT, United States.
Jessica McKenzieResearch Department, Saint Francis Hospital and Medical Center, Hartford CT, United States.
Lisa CookDiabetes and Endocrinology Center, Saint Francis Hospital and Medical Center, Hartford, CT, United States.
Jennifer PuffDiabetes and Endocrinology Center, Saint Francis Hospital and Medical Center, Hartford, CT, United States.
Mary OnoroskiCollaborative Laboratory Services, Trinity Health Of New England, Hartford, CT, United States.
Dorothy B WakefieldResearch Department, Saint Francis Hospital and Medical Center, Hartford CT, United States.
Reginald J EadieTrinity Health Of New England, Hartford, CT, United States.
Steven B KleiboekerViracor, Eurofins Clinical Diagnostics, Lee's Summit, MO, United States.
Patricia NaborsTransfusion Services, Collaborative Laboratory Services, Trinity Health Of New England, Hartford, CT, United States.
Syed A HussainTrinity Health Of New England, Hartford, CT, United States.
Saint Francis Hospital & Medical Center · USHartford Financial Services (United States)Trinity Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 has infected millions worldwide. The virus is novel, and currently there is no approved treatment. Convalescent plasma may offer a treatment option. We evaluated trends of IgM/IgG antibodies/plasma viral load in donors and recipients of convalescent plasma. 114/139 (82 %) donors had positive IgG antibodies. 46/114 donors tested positive a second time by NP swab. Among those retested, the median IgG declined (p < 0.01) between tests. 25/139 donors with confirmed SARS-CoV-2 were negative for IgG antibodies. This suggests that having had the infection does not necessarily convey immunity, or there is a short duration of immunity associated with a decline in antibodies. Plasma viral load obtained on 35/39 plasma recipients showed 22 (62.9 %) had non-detectable levels on average 14.5 days from positive test versus 6.2 days in those with detectable levels (p < 0.01). There was a relationship between IgG and viral load. IgG was higher in those with non-detectable viral loads. There was no relationship between viral load and blood type (p = 0.87) or death (0.80). Recipients with detectable viral load had lower IgG levels; there was no relationship between viral load, blood type or death.

Indexed as

SARS-CoV-2AdultAgedAntibodies, ViralCOVID-19COVID-19 SerotherapyFemaleHumansImmunization, PassiveImmunoglobulin GImmunoglobulin MMaleMiddle AgedAntibodies, ViralImmunoglobulin GImmunoglobulin MAdultsAntigensBlood transfusionCoronavirusCoronavirus infectionsCOVID-19COVID-19 serotherapyHumansImmunoglobulin GImmunoglobulin MPlasmaSARS virusSevere acute respiratory syndromeSevere acute respiratory syndrome coronavirus 2ViralViral load

Identifiers

PMID32883593
PMCPMC7446657
OpenAlexW3080786786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.